Background: Despite distinct advancements in nutritional therapy, malnutrition and growth retardation remain inevitable consequences of chronic liver disease. The global prevalence of chronic liver disease in children is about 3%, with a quarter undernourished. Malnutrition itself is a negative prognostic indicator of survival. Further research is necessary for delivering adequate nutritional support to reduce morbidity and mortality.
Objective: To evaluate the nutritional status and growth of children with chronic liver disease and its contributing factors.
Methods And Study Design: Data were gathered about 21 children aged 7 months to 13.3 years diagnosed with chronic liver disease at Harapan Kita Women and Children Hospital between November 2014 and February 2016. Physical growth and nutritional status were evaluated using anthropometric percentiles and z-scores. Laboratory measurements were made on their first visit.
Results: The mean age of participants was 43.9±47.4 months. Mean weight was 13.4±9.31 kg, and mean length/height was 88.8±27.7 cm. Ten (47.6%) and 3 (14.3%) patients had moderate or severe undernutrition, respectively, and 38% (8 patients) had growth retardation. Of those with good nutritional status, 62.5% were older than 5 years. Malnutrition was correlated with growth failure, a low serum albumin, and elevated aspartate transaminase (p<0.05 in all cases).
Conclusion: Early diagnosis of malnutrition should encourage nutritional support, delay illness progression and increase survival in children with chronic liver disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.6133/apjcn.062017.s10 | DOI Listing |
HPB (Oxford)
January 2025
Hepato-Biliary Center, AP-HP Paul Brousse Hospital, Paris-Saclay University, INSERM Unit 1193, 94800 Villejuif, France. Electronic address:
Background: Liver cirrhosis accounts for more than 90 % of portal hypertension cases, and the other cases are due to noncirrhotic portal hypertension (NCPH). Variceal bleeding is the most life-threatening complication of portal hypertension and its primary treatment is medical according to the Baveno VII guidelines. This review discusses the evidence on surgical portal decompression for adult patients with NCPH secondary to chronic extrahepatic portal vein obstruction (EHPVO).
View Article and Find Full Text PDFJ Hepatol
January 2025
Department of Hepatology, Sanjay Gandhi Postgraduate institute of medical sciences, Lucknow, UP, INDIA. Electronic address:
Virus Res
January 2025
Medical Research Center, Yuebei People's Hospital, Shantou University Medical College, 512025, Shaoguan, China; Shenzhen Immuthy Biotech Co., Ltd, 518107, Shenzhen, Guangdong, China. Electronic address:
Hepatitis B virus (HBV) represents one of the major pathogenic factor that leads to chronic liver diseases and the development of hepatocellular carcinoma (HCC). The currently approved anti-HBV drugs cannot eradicate the virus or block the development of HCC. HBV nucleocapsid consists of the hepatitis B core antigen (HBcAg) and the HBV relaxed-circular partially double-stranded DNA (rcDNA), indispensable in virus replication.
View Article and Find Full Text PDFImmunity
January 2025
Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB-UGent Center for Inflammation Research, Technologiepark-Zwijnaarde 71, Ghent 9052, Belgium; Department of Biomedical Molecular Biology, Faculty of Science, Ghent University, Ghent, Belgium. Electronic address:
Our understanding of the functional heterogeneity of resident versus recruited macrophages in the diseased liver is limited. A population of recruited lipid-associated macrophages (LAMs) has been reported to populate the diseased liver alongside resident Kupffer cells (KCs). However, the precise roles of these distinct macrophage subsets remain elusive.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.
Background: Hypoxia-inducible factor 1 alpha (HIF-1α) and its related vascular endothelial growth factor (VEGF) may play a significant role in atherosclerosis and their targeting is a strategic approach that may affect multiple pathways influencing disease progression. This study aimed to perform a systematic review to reveal current evidence on the role of HIF-1α and VEGF immunophenotypes with other prognostic markers as potential biomarkers of atherosclerosis prognosis and treatment efficacy.
Methods: We performed a systematic review of the current literature to explore the role of HIF-1α and VEGF protein expression along with the relation to the prognosis and therapeutic strategies of atherosclerosis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!